Pamel (Pantoprazole) is indicated
where suppression of acid secretion is of therapeutic benefit. Pamel (Pantoprazole) is registered for
the following indications:
Ø Peptic ulcer diseases (PUD)
Ø Gastro esophageal reflux diseases (GERD)
Ø Treatment of ulcer resistant to H2 receptor antagonists (H2RAs)
Ø Treatment of ulcers induced by non-steroidal anti-inflammatory drugs (NSAIDs)
Ø Gastrointestinal (GI) bleeding from stress or acid peptic diseases
Ø Eradication of Helicobacter pylori (in combination with antibiotics)
Ø Zollinger-Ellison syndrome
Ø Prophylaxis for acid aspiration syndrome during induction of anaesthesia
Dosage & Administration:
Ø Gastro esophageal reflux disease, 20-40 mg daily for 4 weeks continued for further 4 weeks if not fully healed; may be continued at 20 mg daily ( long-time management), increased to 40 mg daily if symptoms return.
Ø Duodenal ulcer, 40 mg daily for 2 weeks, continued for further 2 weeks if not fully healed.
Ø Duodenal ulcer associated with Helicobacter pylori, Pantoprazole 20 mg 3-4 times daily in combination with appropriate antibiotic. NSAID-induced peptic ulcer: 20 mg daily.
Ø Zollinger-Ellison Syndrome, the recommended oral dosage is one gastro-resistant pantoprazole tablet 20 mg twice daily.
Pamel 20 Tablet: Each enteric coated tablet contains Pantoprazole Sodium Sesquihydrate INN equivalent to Pantoprazole 20 mg.
Pamel 40 Tablet: Each enteric coated tablet contains Pantoprazole Sodium Sesquihydrate INN equivalent to Pantoprazole 40 mg.